Home
Kieran Lamb's Library tagged → View Popular
US up to 55 million swine flu vaccine doses short - The Independent 28th October 2009
"The United States will face a swine flu vaccine shortfall of 45 to 55 million doses by the end of the year but half of the population could still be vaccinated, a senior US official said.
"I don't think we will get to the original goal" of 195 million influenza A(H1N1) vaccine doses delivered during the US government's fall vaccination campaign, said Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases."
Haemophiliacs with HIV to sue firm that sold tainted drug in Asia - The Observer 11th October 2009
"Bayer owned company to face victims in Taiwan and Hong Kong over its marketing of infectious blood products"
Swine flu vaccine supplier has to pay back millions - The Observer 11th October 2009
"US pharmaceutical giant Baxter accused of overcharging Medicaid programmes"
Abbott buys pharmaceutical arm of Solvay for $6.6bn - The Guardian 28th September 2009
Abbott Laboratories is buying the pharmaceutical business of Belgian chemicals maker Solvay for $6.6bn (£4.15bn) in a move to further expand internationally and add to its product portfolio.
British doctor faces action over claims of 'ghost writing' for US drug company - The Guardian 18th September 2009
Doctors have been agreeing to be named as authors on studies written by employees of the pharmaceutical industry, giving greater credibility to medical research, according to new evidence.
The Guardian has learned that one of Britain's leading bone specialists is facing disciplinary action over accusations that he was involved in "ghost writing".
Letters: The need for HIV patent pools is urgent - The Guardian 15th September 2009
Unitaid welcomes GlaxoSmithKline's renewed interest in the Unitaid patent pool initiative for HIV/Aids medicines and its openness to taking a flexible approach to managing intellectual property (Letters, 10 September); and GlaxoSmithKline urged to pool its patents on HIV drugs, 7 September).
Space age technology used to spot fake medicines - Daily Telegraph 8th September 2009
Space-age technology is being used in a new, quick way of detecting fake pharmaceuticals, the University of Leicester said.
GlaxoSmithKline urged to pool its patents on HIV drugs - The Guardian 7th September 2009
Leading UK and international organisations have written to Britain's largest drug company urging it to pool its patents on HIV medicines to help save millions of lives in developing countries.
A letter from 15 organisations, including the Stop Aids Campaign, Médecins Sans Frontières, Unicef and Christian Aid, calls on GlaxoSmithKline to join a patent pool being put together by Unitaid, which aims to improve access to drugs for HIV/Aids and other diseases in poor countries.
Doctor got into colleague's bed after she collapsed - Daily Telegraph 2nd September 2009
A doctor got into a colleague’s bed during a business trip to America after she collapsed while drinking a gin and tonic with him in a bar.
Soaring drugs bill 'threatens to bankrupt NHS' - The Guardian 29th August 2009
The NHS risks bankruptcy from a soaring drugs bill which is outstripping Britain's GDP growth, according to a report published today.
The report, by the pressure group Compass, calls for regulation of the pharmaceutical industry to curb prices. The coalition of academics, campaigners and union leaders also warns that the billions spent by big pharma on seminars and conferences gives companies undue influence over doctors.
Shortage of medicines sees patients being admitted to hospital - Daily Telegraph 24th August 2009
Patients are suffering “extreme distress” and are even being admitted to hospital due to a shortage of certain medicines, pharmacists have warned.
David Prosser: A dose of sense about GSK profits - The Independent 23rd July 2009
Outlook GlaxoSmithKline no doubt saw it coming, but the pharmaceuticals giant is still entitled to be annoyed by the hysterical reaction by some to its latest sales figures. Its half-year update showed, hardly surprisingly, a big increase in demand for its anti-flu drug Relenza, plus huge pre-orders for the H1N1 vaccine GSK expects to have ready this autumn
James Moore: Swines? No, they deserve it - The Independent 23rd July 2009
Step forward Andrew Witty, this week's epitome of corporate evil. Mr Witty is chief executive of GlaxoSmithKline and his company stands to make an awful lot of money out of swine flu.\n\nWhat is more, he had the cheek to refuse to make any kind of apology for that as the company presented its results yesterday. Mr Witty would be well advised to make like an underperforming England football manager and stick his head in a paper bag for a few weeks.
Drugs giant GlaxoSmithKline predicts swine flu gold rush - The Guardian 22nd July 2009
Britain's biggest pharmaceutical company is preparing to sell £3bn worth of swine flu drugs this year, it emerged today.\n\nGlaxoSmithKline revealed its vaccine, one of the world's first, could be available by September after the UK government placed advance orders for 60m doses.
Flu treatment output 'to triple' - BBC Health News 22nd July 2009
Drugs giant GlaxoSmithKline says it expects to triple capacity of its flu treatment Relenza to 190 million treatments per year.
Glaxo also said it had received contracts for 195 million doses of the H1N1 vaccine for swine flu, adding that it was on track to meet the orders.
International development minister urges firms to pool HIV patents - The Observer 12th July 2009
Drug companies should give up their patent rights to HIV medicines to help prevent the deaths of millions of people in poor countries, a British government minister will say this week.
The international development minister, Mike Foster, will call on pharmaceutical companies to put lives before profits, as the all-party parliamentary group on Aids publishes a report this week detailing the scale of the "treatment timebomb".
Scheme to let new drugs bypass NHS value watchdog - The Guardian 10th July 2009
Drug companies with "innovative" medicines would be able to bypass current safeguards and sell to the NHS at a high price under a fast-track procedure to be proposed next week by the Office for Life Sciences (OLS), run by science minister Lord Drayson.
The proposal, in a blueprint being prepared behind closed doors with input from the pharmaceutical industry, will effectively undermine the present system of approving medicines for the NHS.
Fear for cancer patients as vital drugs are exported - The Observer 5th July 2009
Supplies of vital medicines, including those used in the fight against cancer, are running short because UK pharmacies and drug wholesalers are selling them abroad to maximise profits.
The situation is becoming so critical that last night major pharmaceutical companies and leading charities called for the government to introduce new regulations to ensure supplies will be guaranteed in the future.
The unbearable cost of living - The Sunday Times 7th June 2009
Why does nobody take responsibility for negotiating the price of the NHS's drugs down and delivering value for money?
Drug giants urged to create patent pools - The Guardian 24th March 2009
A government minister will today challenge drug companies to help the developing world by giving up their patent rights to compounds that could be used in cures for neglected diseases and medicines for children with HIV.
Ivan Lewis, the minister for international development, said it was reasonable to expect the drug giants to do more. "Now is the time for industry to step up to the mark," he said.
Selected Tags
Related Tags
UHN (40)- Health (39)
- News (39)
- The Guardian (17)
- Ethics (14)
- Drug Therapy (12)
- Economics (7)
- Immunisation (6)
- Influenza (6)
- H1N1 (6)
- Financial Management (6)
- Health Economics (6)
- Pandemic (5)
- The Observer (5)
- Fraud (5)
- BBC Health News (5)
- Health Service Economics (5)
- The Independent (4)
- Acquired Immune Deficiency Syndrome (4)
Sponsored Links
Top Contributors
Highlighter, Sticky notes, Tagging, Groups and Network: integrated suite dramatically boosting research productivity. Learn more »
Join Diigo